Radiopharm Theranostics (RADX) Cash & Equivalents (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Radiopharm Theranostics (RADX) has disclosed Cash & Equivalents for 2 consecutive years, with $29.1 million as the latest value for Q2 2025.

• On a quarterly basis, Cash & Equivalents rose 56.75% to $29.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $29.1 million, a 56.75% increase, with the full-year FY2025 number at $29.1 million, up 56.75% from a year prior.
• Cash & Equivalents was $29.1 million for Q2 2025 at Radiopharm Theranostics, up from $18.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $29.1 million in Q2 2025 to a low of $18.6 million in Q2 2024.

Peer Comparison